Title: The expression of multidrug resistant proteins in colorectal carcinoma and their clinical significance
Abstract: Objective Multidrug resistance(MDR) is not only the main reason of the failure of chemotherapy,but also the largest obstacle to increase the survival rate in colorectal carcinoma.MDR of colorectal carcinoma is a complex procedure involved in multiple genes and mutiple pathways.Combined examination of resistance related genes in colorectal carcinoma tissues has an important clinical significance.The aim of this study is to explore the relationship among the expression,coexpression of seven multidrug resistance factors of colorectal carcinoma tissues and clinicopathological characteristics in patients with colorectal carcinoma.Methods Immunohistochemical staining(EnVision method) was used to evaluated the expression of P-gly-coprotein(P-gp),glutathione S-transferase-π(GST-π),topoisomerase Ⅱ(TopoⅡ),Thymidylate synthase(TS),Methylguanine-DNA methyltransferase(MGMT),lung resistance protein(LRP),and multidrug resistance associated protein(MRP) in cancer tissues from 63 patients with colorectal carcinoma.Results The positive rate of P-gp,GST-π,TopoⅡ,TS,MGMT,LRP and MRP was 34(54%),45(71%),39(62%),42(67%),36(57%),50(79%),19(30%) respectively.The expression of all multidrug resistance factors is not relative to sex and age.MGMT and LRP expression were significantly correlated with lymph node metastases.P-gp,GST-π,TopoⅡ and MRP were significantly correlated with various grade of cell.TS,MGMT and LRP were significantly correlated with clinical staging.P-gp and MGMT were significantly correlated with survival rate.Conclusion The higher co-expression rate and positive relativity indicate MDR in colorectal carcinoma is affected by various multidrug resistance factors.It is important to detect conjoinedly various multidrug resistance factors.
Publication Year: 2007
Publication Date: 2007-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot